 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Cabaletta Bio, Inc. (CABA) focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. 
The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease.
Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris.
It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. Shares are heading higher in an upward trading channel. Note that the mean target of analysts is $20.51 for the stock. There is one estimate of $34. We expect higher share prices for this stock.
Entry Point: $15.75
Trading range: $0.61 to $19.34
Stop Loss: $14.75
Target Price: $17.50
